Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study

Abstract The objective of this study was to assess the efficacy and tolerability of minocycline add-on to risperidone in treatment of negative symptoms of patients with chronic schizophrenia. In a randomized double-blind placebo-controlled study, 40 patients with chronic schizophrenia who were stabi...

Full description

Saved in:
Bibliographic Details
Published in:Psychiatry research 2014-03, Vol.215 (3), p.540-546
Main Authors: Khodaie-Ardakani, Mohammad-Reza, Mirshafiee, Omid, Farokhnia, Mehdi, Tajdini, Masih, Hosseini, Seyed-Mohammad-Reza, Modabbernia, Amirhossein, Rezaei, Farzin, Salehi, Bahman, Yekehtaz, Habibeh, Ashrafi, Mandana, Tabrizi, Mina, Akhondzadeh, Shahin
Format: Article
Language:English
Subjects:
Adult
Adult and adolescent clinical studies
Anti-Bacterial Agents - administration & dosage
Antipsychotic Agents - administration & dosage
Biological and medical sciences
Double-Blind Method
Drug Therapy, Combination
Female
Glutamate
Humans
Male
Medical sciences
Middle Aged
Minocycline
Minocycline - administration & dosage
Negative symptoms
Neuropharmacology
Pharmacology. Drug treatments
Psychiatric Status Rating Scales
Psychiatry
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Psychoses
Risperidone - administration & dosage
Schizophrenia
Schizophrenia - drug therapy
Schizophrenic Psychology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The objective of this study was to assess the efficacy and tolerability of minocycline add-on to risperidone in treatment of negative symptoms of patients with chronic schizophrenia. In a randomized double-blind placebo-controlled study, 40 patients with chronic schizophrenia who were stabilized on risperidone for a minimum duration of eight weeks were recruited. The patients were randomly assigned to minocycline (titrated up to 200 mg/day) or placebo in addition to risperidone (maximum dose of 6 mg/day) for eight weeks. Positive and Negative Syndrome Scale (PANSS), Hamilton Depression Rating Scale, and Extrapyramidal Syndrome Rating Scale were used. Thirty-eight patients completed the study. Significant time×treatment interaction for negative [ F (2.254,85.638)=59.046, P
ISSN:0165-1781
1872-7123
DOI:10.1016/j.psychres.2013.12.051